MA33023B1 - Formulation d'anticorps - Google Patents

Formulation d'anticorps

Info

Publication number
MA33023B1
MA33023B1 MA33984A MA33984A MA33023B1 MA 33023 B1 MA33023 B1 MA 33023B1 MA 33984 A MA33984 A MA 33984A MA 33984 A MA33984 A MA 33984A MA 33023 B1 MA33023 B1 MA 33023B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical formulations
antibodies
formulation
aggregate
beta
Prior art date
Application number
MA33984A
Other languages
Arabic (ar)
English (en)
Inventor
Joachim Momm
Hans-Joachim Wallny
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33023(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33023B1 publication Critical patent/MA33023B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur des formulations pharmaceutiques, en particulier sur de nouvelles formulations pharmaceutiques dans lesquelles l'ingrédient actif comprend des anticorps humains dirigés contre l'interleukine I bêta humaine (IL-²1), en particulier l'anticorps ACZ885, sur des formulations pharmaceutiques qui sont stables et exemptes d'agrégat lors du stockage et de l'administration.
MA33984A 2008-12-10 2009-12-09 Formulation d'anticorps MA33023B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (fr) 2008-12-10 2008-12-10 Formulation d'anticorps
PCT/EP2009/066675 WO2010066762A1 (fr) 2008-12-10 2009-12-09 Formulation d'anticorps

Publications (1)

Publication Number Publication Date
MA33023B1 true MA33023B1 (fr) 2012-02-01

Family

ID=40637230

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33984A MA33023B1 (fr) 2008-12-10 2009-12-09 Formulation d'anticorps

Country Status (31)

Country Link
US (3) US20110236398A1 (fr)
EP (4) EP2196476A1 (fr)
JP (6) JP6143416B2 (fr)
KR (2) KR101762966B1 (fr)
CN (3) CN104399076B (fr)
AU (1) AU2009324371B2 (fr)
BR (1) BRPI0922730A2 (fr)
CA (1) CA2745938C (fr)
CL (1) CL2011001406A1 (fr)
CO (1) CO6361952A2 (fr)
CY (2) CY1117735T1 (fr)
DK (2) DK2376533T3 (fr)
EC (1) ECSP11011192A (fr)
ES (2) ES2579835T3 (fr)
HR (2) HRP20160754T1 (fr)
HU (2) HUE028408T2 (fr)
IL (3) IL264316B2 (fr)
LT (1) LT3072906T (fr)
MA (1) MA33023B1 (fr)
MX (1) MX2011006242A (fr)
MY (2) MY157772A (fr)
NZ (1) NZ592918A (fr)
PE (1) PE20120342A1 (fr)
PL (2) PL3072906T3 (fr)
PT (2) PT3072906T (fr)
RU (2) RU2745601C2 (fr)
SI (2) SI3072906T1 (fr)
SM (1) SMT201600222B (fr)
TN (1) TN2011000229A1 (fr)
WO (1) WO2010066762A1 (fr)
ZA (1) ZA201103362B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (fr) * 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP3409289B1 (fr) 2010-02-26 2020-09-30 Novo Nordisk A/S Compositions contenant un anticorps stable
RS59830B1 (sr) 2010-03-01 2020-02-28 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
EA032336B1 (ru) 2010-09-17 2019-05-31 Баксалта Инкорпорейтид Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (fr) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
AP2014007680A0 (en) 2011-12-02 2014-06-30 Novartis Ag Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
ES2732243T3 (es) * 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
KR102213535B1 (ko) * 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151663A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines membranaires
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP3916013A1 (fr) 2012-09-20 2021-12-01 MorphoSys AG Traitement de la polyarthrite rhumatoïde avec anticorps dirigé contre gm-csf
AU2013344796B2 (en) * 2012-11-16 2016-11-10 Novartis Ag Use of IL-1 beta binding antibodies for treating peripheral arterial disease
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016515515A (ja) 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 抗プロラクチン受容体抗体製剤
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015181757A1 (fr) * 2014-05-28 2015-12-03 Nono Inc. Formulation lyophilisée de tat-nr2b9c avec capteur d'acétylation
AU2015310879A1 (en) * 2014-09-03 2017-03-02 Medimmune Limited Stable anti-IL-4R-alpha antibody formulation
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2016077451A1 (fr) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anticorps anti-endogline et leurs utilisations
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
CN108367072B (zh) 2015-12-07 2022-12-27 默克专利股份有限公司 含抗-pd-l1抗体avelumab的水性药物制剂
CN109415440B (zh) * 2016-06-27 2022-12-06 莫佛塞斯公司 抗-cd19抗体制剂
KR20190032436A (ko) * 2016-07-21 2019-03-27 노파르티스 아게 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도
AU2017333367A1 (en) * 2016-09-27 2019-04-04 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
MY195529A (en) 2016-11-18 2023-01-30 Astellas Pharma Inc Novel Anti-Human MUC1 Antibody Fab Fragment
US20190048072A1 (en) * 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
US20200207848A1 (en) * 2017-09-13 2020-07-02 Novartis Ag Use of il-1b binding antibodies for the treatment of alcoholic hepatitis
TW202003036A (zh) * 2018-03-23 2020-01-16 德商艾伯維德國有限及兩合公司 穩定水性抗-tau抗體調配物
WO2019221269A1 (fr) 2018-05-17 2019-11-21 アステラス製薬株式会社 COMPLEXE AYANT UN FRAGMENT Fab D'ANTICORPS ANTI-MUC1 HUMAINE, UN LIEUR PEPTIDIQUE ET/OU UN LIGAND
MY205764A (en) * 2018-10-10 2024-11-12 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
SG11202108627SA (en) * 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
US20240052026A1 (en) * 2020-12-22 2024-02-15 Bio-Thera Solutions, Ltd. Stable antibody formulation, preparation method therefor, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (fr) 1993-07-09 1995-01-19 Smithkline Beecham Corporation ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
CA2226575C (fr) 1995-07-27 2011-10-18 Genentech, Inc. Formulation de proteine lyophilisee isotonique et stable
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
MXPA02012867A (es) 2000-06-29 2003-09-05 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ES2392073T3 (es) * 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
KR20070107079A (ko) * 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
LT2620450T (lt) * 2005-03-08 2019-02-11 Pfizer Products Inc. Anti-ctla-4 antikūnų kompozicijos
EP1888637A2 (fr) * 2005-05-19 2008-02-20 Amgen Inc. Compositions et procedes permettant d'accroitre la stabilite d'un anticorps
EP2848258B1 (fr) 2005-10-26 2017-12-13 Novartis AG Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
MX2009010179A (es) * 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
EP2196476A1 (fr) * 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
WO2010100179A2 (fr) 2009-03-05 2010-09-10 Novartis Ag Système de gel autoformé pour administration de médicament à libération lente
WO2012028683A1 (fr) 2010-09-02 2012-03-08 Novartis Ag Système de gel d'anticorps pour administration de médicament prolongée

Also Published As

Publication number Publication date
JP2026021446A (ja) 2026-02-10
KR20170044211A (ko) 2017-04-24
PT2376533T (pt) 2016-07-13
CA2745938C (fr) 2018-04-24
IL212922B (en) 2019-02-28
JP2023109938A (ja) 2023-08-08
JP6143416B2 (ja) 2017-06-07
JP2020203889A (ja) 2020-12-24
KR101762966B1 (ko) 2017-07-31
RU2011127913A (ru) 2013-01-20
DK3072906T3 (da) 2021-12-13
WO2010066762A1 (fr) 2010-06-17
SMT201600222B (it) 2016-08-31
JP2018168158A (ja) 2018-11-01
IL264316B1 (en) 2023-09-01
CN102245639B (zh) 2014-12-24
HUE056626T2 (hu) 2022-02-28
IL264316B2 (en) 2024-01-01
US20110236398A1 (en) 2011-09-29
SI3072906T1 (sl) 2022-01-31
HRP20160754T1 (hr) 2016-08-12
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
ZA201103362B (en) 2012-01-25
CY1124844T1 (el) 2022-11-25
AU2009324371A1 (en) 2011-06-23
BRPI0922730A2 (en) 2018-11-06
CN104399076B (zh) 2021-09-14
RU2563179C2 (ru) 2015-09-20
JP2015231997A (ja) 2015-12-24
ES2900624T3 (es) 2022-03-17
RU2015132431A3 (fr) 2018-12-24
PE20120342A1 (es) 2012-04-24
RU2015132431A (ru) 2018-12-24
LT3072906T (lt) 2021-12-27
CA2745938A1 (fr) 2010-06-17
CN102245639A (zh) 2011-11-16
EP3792282A1 (fr) 2021-03-17
IL264316A (en) 2019-02-28
IL276622A (en) 2020-09-30
US8623367B2 (en) 2014-01-07
US20200384108A1 (en) 2020-12-10
EP2376533B1 (fr) 2016-03-30
AU2009324371B2 (en) 2013-10-10
HUE028408T2 (en) 2016-12-28
TN2011000229A1 (en) 2012-12-17
HK1159130A1 (zh) 2012-07-27
CN104399076A (zh) 2015-03-11
ES2579835T3 (es) 2016-08-17
MY166050A (en) 2018-05-22
JP7286595B2 (ja) 2023-06-05
SI2376533T1 (sl) 2016-07-29
HRP20211899T1 (hr) 2022-03-04
CO6361952A2 (es) 2012-01-20
ECSP11011192A (es) 2011-08-31
KR20120009421A (ko) 2012-01-31
PL2376533T3 (pl) 2016-09-30
PT3072906T (pt) 2021-12-14
EP3072906A1 (fr) 2016-09-28
US20120315285A1 (en) 2012-12-13
JP2012511540A (ja) 2012-05-24
CY1117735T1 (el) 2017-05-17
MX2011006242A (es) 2011-06-24
RU2745601C2 (ru) 2021-03-29
CN114225022A (zh) 2022-03-25
IL212922A0 (en) 2011-07-31
PL3072906T3 (pl) 2022-01-24
EP2376533A1 (fr) 2011-10-19
EP2196476A1 (fr) 2010-06-16
DK2376533T3 (en) 2016-06-27
EP3072906B1 (fr) 2021-09-08
CL2011001406A1 (es) 2012-03-30

Similar Documents

Publication Publication Date Title
MY157772A (en) Antibody formulation
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
AR130402A2 (es) Formulaciones de anticuerpos anti-pdl1
CY1125697T1 (el) Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
BR112012002080A2 (pt) formulações farmacêuticas estáveis altamente concentradas de um anticorpo anti-her2 farmaceuticamente ativo, uso de uma formulação, dispositivo de injeção e kit
SV2010003517A (es) Anticuerpos anti-il-12/23 p40, epitopes, formulaciones, composiciones, metodos y usos "ref. cen5196svpct"
UA111825C2 (uk) Стабілізований препарат, що містить антитіло проти ngf
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2015012549A (es) Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
EP2130552A4 (fr) Composition pharmaceutique comportant un anticorps anti-grp 78 en tant qu'ingredient actif
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MA55033A (fr) Formulation d'anticorps thérapeutique
BRPI0909296A2 (pt) uso de pelo menos um princípio ativo, e, composições cosmética, farmacêutica e/ou dermatológica
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
TR200806300A2 (tr) Çözünürlük artırıcı farmasötlk formulasyon
MA55809A (fr) Formulation d'anticorps anti-il-6
EA200701010A1 (ru) Препарат гепирона с высокой дозировкой и длительным высвобождением
EA202191570A1 (ru) Композиции для доставки терапевтических средств, способы их применения и получения
TH121146A (th) สูตรผสมแอนติบอดี้
TR200806299A2 (tr) Çözünürlük artırıcı farmasötik formülasyon